David Sweetser, owner of Providence's Superman building, dies at 70
Arrangements for services have not yet been scheduled.
Alexa Gagosz can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 minutes ago
- Business Upturn
Aurobindo Pharma share: HSBC, Motilal Oswal, Nuvama maintain ‘Buy'; Avendus retains ‘Reduce' as brokerages assess US outlook and margin risks
Shares of Aurobindo Pharma have drawn mixed reactions from top brokerages following its recent earnings performance. While HSBC, Motilal Oswal, and Nuvama continue to maintain a 'Buy' rating, Avendus has retained a more cautious 'Reduce' stance, citing near-term margin and execution risks in the US segment. Motilal Oswal on Aurobindo Pharma share: Maintains 'Buy', TP cut to ₹1,300 Motilal Oswal Financial Services has maintained its 'Buy' rating on Aurobindo Pharma but lowered the target price to ₹1,300 from ₹1,365. The brokerage noted strong growth in the EU and ARV segments but flagged continued margin pressure as a drag on profitability. EBITDA margin guidance remains unchanged at 20–21% for FY26. Motilal is optimistic about the Lanett acquisition improving profitability and expects the company to file its first US biosimilar in FY26. Earnings estimates for FY26/FY27 were cut by 8%/7% due to pricing headwinds and startup costs at Pen-G and China units. Avendus on Aurobindo Pharma share: Maintains 'Reduce', TP cut to ₹1,145 Avendus has reiterated its 'Reduce' rating with a revised target price of ₹1,145, down from ₹1,220. The firm expects US sales (excluding gRevlimid) to grow at a 9% CAGR over FY25–27E, driven by recovery in injectables and oral solids. EU revenues are expected to grow at a 14% CAGR, aided by new launches and China/Vizag-based supplies. However, the brokerage expressed concerns over delays in monetizing complex assets such as biosimilars and LA injectables, which are now expected to contribute meaningfully only post-FY28. Avendus projects a 15% EPS CAGR (ex-gRevlimid and Pen-G) through FY27 and sees the Lanett acquisition turning EPS-neutral by FY27. EPS estimates have been revised down by 9%/7% for FY26/FY27 due to lower sales and margin risks. HSBC on Aurobindo Pharma share: Maintains 'Buy', TP cut to ₹1,255 HSBC continues to maintain a 'Buy' call on Aurobindo Pharma, cutting its target price to ₹1,255. The brokerage flagged a Q1 miss driven by weaker-than-expected gRevlimid sales, US channel destocking, and pricing pressure in the API business. It highlighted Europe as a bright spot in the company's portfolio. HSBC remains constructive on future margin support from new plant supplies (Pen-G, Vizag, China) and expects volume-led growth to sustain. The brokerage is also watching for closure on the Lanett portfolio acquisition, which could add to long-term growth momentum. Nuvama on Aurobindo Pharma share: Maintains 'Buy', TP reduced to ₹1,445 Nuvama Institutional Equities has also maintained its 'Buy' rating while trimming the target price slightly to ₹1,445 from ₹1,460. The firm highlighted that gross margins remained resilient despite a decline in gRevlimid contributions. Ex-gRevlimid EBITDA margins expanded ~100 bps YoY. Key near-term triggers include the ramp-up of Pen-G and China units, MIP implementation, closure of the Lanett acquisition, and new injectable filings. Nuvama has trimmed its FY27E EPS forecast by around 2%, factoring in near-term execution risks. With varying degrees of optimism, brokerages remain focused on Aurobindo's US trajectory, biosimilar launches, and integration of recent acquisitions as key determinants of its medium-term growth story. Disclaimer: The views and investment recommendations expressed in this article are those of the respective brokerages. These do not represent the views of Business Upturn and do not constitute investment advice. Investors are advised to consult their financial advisors before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
Yahoo
35 minutes ago
- Yahoo
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson's Disease
CAMBRIDGE, Mass., August 06, 2025--(BUSINESS WIRE)--Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson's disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway's novel, highly brain-penetrant small molecule TRPML1 agonist. The study aims to investigate whether activating TRPML1 by a novel, small molecule modulator, will enhance the lysosomal membrane calcium ion channel to restore lysosomal function and help with clearance of alpha-synuclein, the protein that is linked to the disease. "We are honored to receive this generous grant from The Michael J. Fox Foundation," said Valerie Cullen, PhD, Principal Investigator and SVP of Research and Translation at Lysoway. "TRPML1 is a high value target due to its pivotal role in sensing and responding to cellular stress. By activating this ion channel, we can engage multiple beneficial pathways that restore autophagy/lysosomal homeostasis and bolster cellular resilience. Our lead development candidate is both orally bioavailable and highly brain-penetrant, offering strong potential to modify disease progression in Parkinson's Disease." Yongchang Qiu, PhD, Founder and Chief Executive Officer of Lysoway Therapeutics, added "This funding underscores growing confidence in TRPML1 as a compelling target for Parkinson's disease. It will allow us to accelerate development of our lead TRPML1 agonist and to establish key biomarkers for target engagement, with the goal of initiating first-in-human clinical trials early next year." About Lysoway Therapeutics, in Cambridge, MA, Lysoway Therapeutics is a leader in developing therapeutically viable lysosomal ion channel modulators. The company is advancing a pipeline of small molecule activators targeting these channels to treat neurodegenerative diseases. Learn more at View source version on Contacts Media contact: Info@
Yahoo
an hour ago
- Yahoo
Does the Georges Niang deal and Chris Boucher signing mean Boston is focused on the future?
Does the Boston Celtics trading Georges Niang and signing Chris Boucher mean the front office is firmly focused on the future of the team? When news broke that the Celtics were salary dumping Niang's salary into the Utah Jazz' cap space, some fans of the team were not thrilled about the fact that more and more talent seemed headed out the door as this offseason progressed. But then Boston signed the former Toronto Raptors backup big man, with Boucher immediately becoming one of if not the best frontcourt players set to suit up for the Celtics this coming season. What are these moves telling us about what the team is prioritizing for the current season and beyond? The folks behind the "NBC Sports Boston" YouTube channel put together a clip from a recent episode of their "Arbella Early Edition" that saw Chris Forsberg and Michael Holley, and Trenni Casey talk it all over. Check it out below! Listen to "Havlicek Stole the Pod" on: Spotify: iTunes: YouTube: This article originally appeared on Celtics Wire: Does the Niang deal and Boucher signing mean Boston is future-focused?
